Henlius Finds Global Partner For Ophthalmic Bevacizumab
Strikes Deal With Essex Bio-Technology For Biosimilar Avastin Rival
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.